Non-small cell lung cancer continues to show massive promise with new trials, better designs and exciting utilisation of existing therapies. Michael and Josh explore immunotherapy in a \"sandwich setting\" where nivolumab is given before and after surgery. Datopotamab deruxtecan, the new kid on the block, takes on the second-line champion docetaxel. Who will win, and will docetaxel finally be dethroned? And potentially the most promising and exciting addition to this lineup is AZD7789, a new bispecific antibody TIM-3 being added to existing immunotherapy to try and resensitise cancer to PD-1 inhibitors!
Studies discussed in today's episode (subscription may be required)
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}